A phase 1b, multicenter, open-label study of valemetostat in combination with DXd antibody drug conjugates (ADCs), trastuzumab deruxtecan (T-DXd) or datopotamab deruxtecan (Dato-DXd), in patients with solid tumors Meeting Abstract


Authors: Sands, J.; Tolaney, S. M.; Ueno, N. T.; Spira, A. I.; Yamamoto, N.; Janjigian, Y. Y.; Naito, Y.; Damodaran, S.; Meric-Bernstam, F.; Modi, S.; Enzinger, P. C.; Mohapatra, A. S.; Iko, Y.; He, S.; Nakajima, K.; Shitara, K.
Abstract Title: A phase 1b, multicenter, open-label study of valemetostat in combination with DXd antibody drug conjugates (ADCs), trastuzumab deruxtecan (T-DXd) or datopotamab deruxtecan (Dato-DXd), in patients with solid tumors
Meeting Title: 2024 ASCO Annual Meeting
Journal Title: Journal of Clinical Oncology
Volume: 42
Issue: 16 Suppl.
Meeting Dates: 2024 May 31-Jun 4
Meeting Location: Chicago, IL
ISSN: 0732-183X
Publisher: American Society of Clinical Oncology  
Date Published: 2024-06-01
Language: English
ACCESSION: WOS:001275557406175
PROVIDER: wos
DOI: 10.1200/JCO.2024.42.16_suppl.TPS4180
Notes: Meeting Abstract: TPS4180 -- Source: Wos
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Yelena Yuriy Janjigian
    400 Janjigian
  2. Shanu Modi
    268 Modi